RGNX

6 atoms · 跨 1 天 · 首见 2026-06-22 · 最近 2026-06-22

三色: 🟦 fact 6 · 🟥 take 0 · stance ▲4/▼0/◆0

来源: X 6

时态: fresh:6

标签: 好信源:4 · 好数字:2

预测 (forecast) (2)

• 2026-06-22 · expects Type A meeting in July
  Regenxbio expects a Type A meeting in July and plans to resubmit the BLA in Q3 2026.
  tags: 好信源 · → daily
  value: date=July 2026
• 2026-06-22 · plans to resubmit BLA in Q3 2026
  Regenxbio expects a Type A meeting in July and plans to resubmit the BLA in Q3 2026.
  tags: 好信源 · → daily
  value: date=Q3 2026

事实 (fact) (4)

• 2026-06-22 · FDA agreed no additional patients or studies needed for NAVSUNLI BLA resubmission for MPS II/Hunter syndrome
  $RGNX says the FDA agreed no additional patients or studies are needed for its NAVSUNLI BLA resubmission for MPS II / Hunter syndrome.
  tags: 好信源 · → daily
• 2026-06-22 · FDA said existing clinical data sufficient for accelerated approval review
  The FDA said existing clinical data is sufficient for accelerated approval review and no untreated control arm is required.
  tags: 好信源 · → daily
• 2026-06-22 · premarket price change
  收盘价: $7.80; 盘前价: $8.36; 盘前涨幅: +7.15%
  tags: 好数字 · → daily
  value: qty=+7.15% · quote=$8.36
• 2026-06-22 · 股价上涨
  Regenxbio (RGNX) climbs 8% after the Wall Street Journal reported that the FDA has agreed to reverse the rejection of the firm’s rare-disease drug.
  tags: 好数字 · → daily
  value: qty=8% · date=2026-06-22

时间轴 (近 20)

• 2026-06-22 · fact · FDA agreed no additional patients or studies needed for NAVS · → daily
• 2026-06-22 · fact · FDA said existing clinical data sufficient for accelerated a · → daily
• 2026-06-22 · forecast · expects Type A meeting in July · → daily
• 2026-06-22 · forecast · plans to resubmit BLA in Q3 2026 · → daily
• 2026-06-22 · fact · premarket price change · → daily
• 2026-06-22 · fact · 股价上涨 · → daily

← 实体目录 · 系统日志